125 related articles for article (PubMed ID: 33947633)
1. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.
Della Rocca AM; Leonart LP; Ferreira VL; Tonin FS; Steffenello-Durigon G; Del Moral JAG; Fernandez-Llimos F; Pontarolo R
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):514-525. PubMed ID: 33947633
[TBL] [Abstract][Full Text] [Related]
2. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
3. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
4. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
[TBL] [Abstract][Full Text] [Related]
5. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
[TBL] [Abstract][Full Text] [Related]
6. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.
Smyth L; Browne PV; Conneally E; Flynn C; Hayden P; Jeffers M; O'Brien D; Quinn F; Kelly J; Perera M; Crotty GM; Leahy M; Hennessy B; Jackson F; Ryan M; Vandenberghe E
Ir J Med Sci; 2016 Nov; 185(4):773-777. PubMed ID: 25843016
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
[TBL] [Abstract][Full Text] [Related]
8. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
[TBL] [Abstract][Full Text] [Related]
9. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
[TBL] [Abstract][Full Text] [Related]
10. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
12. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Mead GM; Barrans SL; Qian W; Walewski J; Radford JA; Wolf M; Clawson SM; Stenning SP; Yule CL; Jack AS; ;
Blood; 2008 Sep; 112(6):2248-60. PubMed ID: 18612102
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
Xiao J; Du S; Dai G; Gao G; Yang D; Zhao H
Sci Rep; 2017 May; 7(1):1905. PubMed ID: 28507339
[TBL] [Abstract][Full Text] [Related]
14. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
Jakobsen LH; Ellin F; Smeland KB; Wästerlid T; Christensen JH; Jørgensen JM; Josefsson PL; Øvlisen AK; Holte H; Blaker YN; Grauslund JH; Bjørn J; Molin D; Lagerlöf I; Smedby KE; Colvin K; Thanarajasingam G; Maurer MJ; Habermann TM; Song KW; Zhu KY; Gerrie AS; Cheah CY; El-Galaly TC
Br J Haematol; 2020 May; 189(4):661-671. PubMed ID: 32017050
[TBL] [Abstract][Full Text] [Related]
15. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
[TBL] [Abstract][Full Text] [Related]
16. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
Tauro S; Cochrane L; Lauritzsen GF; Baker L; Delabie J; Roberts C; Mahendra P; Holte H
Am J Hematol; 2010 Apr; 85(4):261-3. PubMed ID: 20201088
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
[TBL] [Abstract][Full Text] [Related]
19. [Outcome of children and adolescents with Burkitt lymphoma and diffuse large B cell lymphoma treated with a modified NHL-BFM-90 protocol].
Sun XF; Zhen ZJ; Xia Y; Lin SX; Zhu J; Wang J; Lu SY; Sun FF; Chen Y; Zhang F; Cai RQ; Li PF
Zhonghua Xue Ye Xue Za Zhi; 2013 Dec; 34(12):1032-7. PubMed ID: 24369160
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]